Tirzepatide.
Dual GLP-1 / GIP agonist for stronger response in metabolically resistant cases.
What Tirzepatide does.
Clinical effects most commonly reported. Individual response varies — your physician sets the appropriate cycle and dose.
- Combined GLP-1 and GIP receptor activity for compounding metabolic effect
- Often produces faster bodyweight movement than Semaglutide
- Stronger fit for higher-BMI or insulin-resistant presentations
- Subcutaneous injection — once weekly
Tirzepatide adds GIP-receptor activity on top of GLP-1, which compounds the metabolic effect. Your physician decides between Semaglutide and Tirzepatide based on history and response.
Get Tirzepatide.
Start an inquiry, or send a question first.
Prescription products require a consultation with a licensed clinician through our independent clinical partner. Compounded medications are not FDA-approved, and statements about them have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Results may vary. Consult your physician before starting any protocol. Certain materials on this website, including text, images, and other media, may be generated or enhanced using artificial intelligence technologies.